Brokerages Set Cryolife Inc (NYSE:CRY) Target Price at $33.50

Shares of Cryolife Inc (NYSE:CRY) have been given a consensus rating of “Buy” by the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $33.50.

A number of equities research analysts recently issued reports on CRY shares. Canaccord Genuity upped their price objective on shares of TELUS from C$51.00 to C$52.00 in a report on Wednesday, May 1st. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of SCYNEXIS in a report on Sunday, May 12th. ValuEngine upgraded shares of Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Zacks Investment Research cut shares of Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Finally, TheStreet cut shares of Wayside Technology Group from a “b-” rating to a “c” rating in a report on Wednesday, May 22nd.

In other Cryolife news, Director Ronald D. Mccall sold 3,700 shares of the company’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $28.74, for a total transaction of $106,338.00. Following the completion of the sale, the director now directly owns 139,162 shares in the company, valued at $3,999,515.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Scott B. Capps sold 2,000 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $28.55, for a total transaction of $57,100.00. Following the sale, the vice president now owns 141,079 shares of the company’s stock, valued at $4,027,805.45. The disclosure for this sale can be found here. Insiders have sold 99,609 shares of company stock valued at $3,112,863 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Cryolife by 2.8% during the fourth quarter. BlackRock Inc. now owns 5,533,113 shares of the medical equipment provider’s stock valued at $157,030,000 after acquiring an additional 152,026 shares during the period. Macquarie Group Ltd. lifted its stake in shares of Cryolife by 0.3% in the fourth quarter. Macquarie Group Ltd. now owns 1,635,234 shares of the medical equipment provider’s stock valued at $46,408,000 after buying an additional 5,474 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Cryolife by 41.5% in the first quarter. William Blair Investment Management LLC now owns 533,110 shares of the medical equipment provider’s stock valued at $15,551,000 after buying an additional 156,485 shares during the period. Wasatch Advisors Inc. lifted its stake in shares of Cryolife by 50.9% in the first quarter. Wasatch Advisors Inc. now owns 498,176 shares of the medical equipment provider’s stock valued at $14,532,000 after buying an additional 168,125 shares during the period. Finally, Royce & Associates LP lifted its stake in shares of Cryolife by 34.4% in the first quarter. Royce & Associates LP now owns 371,417 shares of the medical equipment provider’s stock valued at $10,834,000 after buying an additional 95,109 shares during the period. Institutional investors own 71.23% of the company’s stock.

Shares of NYSE:CRY opened at $30.07 on Wednesday. The company has a market capitalization of $1.12 billion, a PE ratio of 115.65 and a beta of 0.59. Cryolife has a 1 year low of $23.99 and a 1 year high of $36.05. The stock has a fifty day simple moving average of $29.79. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69.

Cryolife (NYSE:CRY) last issued its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.04. The firm had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $66.37 million. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. Cryolife’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 earnings per share. On average, equities analysts anticipate that Cryolife will post 0.31 earnings per share for the current year.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Story: Should I follow buy, hold and sell recommendations?

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.